Background: The increasing demand for liver transplantation has led to considerable changes in characteristics of donors and recipients. This study evaluated the short- and long-term mortality of recipients with and without hepatocellular carcinoma (HCC) in the UK between 1997 and 2016.

Methods: First-time elective adult liver transplant recipients in the UK were identified and four successive eras of transplantation were compared. Hazard ratios (HRs) comparing the impact of era on short-term (first 90 days) and longer-term (from 90 days to 5 years) mortality were estimated, with adjustment for recipient and donor characteristics.

Results: Some 1879 recipients with and 7661 without HCC were included. There was an increase in use of organs donated after circulatory death (DCD), from 0 per cent in era 1 to 35·2 per cent in era 4 for recipients with HCC, and from 0·2 to 24·1 per cent for non-HCC recipients. The 3-year mortality rate decreased from 28·3 per cent in era 1 to 16·9 per cent in era 4 (adjusted HR 0·47, 95 per cent c.i. 0·35 to 0·63) for recipients with HCC, and from 20·4 to 9·3 per cent (adjusted HR 0·44, 0·36 to 0·53) for those without HCC. Comparing era 4 with era 1, improvements were more marked in short-term than in long-term mortality, both for recipients with HCC (0-90 days: adjusted HR 0·20, 0·10 to 0·39; 90 days to 5 years: adjusted HR 0·52, 0·35 to 0·75; P = 0·043) and for non-HCC recipients (0-90 days: adjusted HR 0·32, 0·24 to 0·42; 90 days to 5 years: adjusted HR 0·52, 0·40 to 0·67; P = 0·024).

Conclusion: In the past 20 years, the mortality rate after liver transplantation has more than halved, despite increasing use of DCD donors. Improvements in overall survival can be explained by decreases in short-term and longer-term mortality.

Download full-text PDF

Source
http://dx.doi.org/10.1002/bjs.11451DOI Listing

Publication Analysis

Top Keywords

cent era
16
long-term mortality
12
liver transplantation
12
90 days 5 years
12
recipients hcc
12
recipients
9
short- long-term
8
hepatocellular carcinoma
8
mortality recipients
8
non-hcc recipients
8

Similar Publications

Background: In spite of spectacular advances in the treatment of multiple myeloma, a majority of patients will die from this disease or related complications. While a great amount of focus has been dedicated to the development of novel therapies, little attention has been paid to latter stages of patient follow-up.

Patients And Methods: In order to describe patient management during this critical period as well as the immediate causes and circumstances of death, we have analyzed a single center series of 100 patients diagnosed with myeloma who died between 2016 and 2021.

View Article and Find Full Text PDF

Diagnoses of children living with HIV before and during the COVID-19 pandemic.

S Afr J Infect Dis

October 2024

Division of Epidemiology and Biostatistics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Article Synopsis
  • * Over 215 diagnoses were recorded for 96 children, with the most common being unspecified HIV disease, tuberculosis (TB), pneumonia, encephalopathy, and malnutrition; a significant number of cases were classified as advanced HIV disease.
  • * Despite extensive COVID-19 screening, no cases were found among CLHIV, emphasizing the ongoing challenge of managing AHD and the importance of improved documentation for better health outcomes.
View Article and Find Full Text PDF

Real-world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study.

ESC Heart Fail

November 2024

Faculty of Medicine and University Hospital Cologne, Clinic III for Internal Medicine, University of Cologne, Cologne, Germany.

Aims: Data on the clinical profiles of patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM) in the post-approval era of tafamidis 61 mg are lacking. Study aims were characterization of contemporary ATTR-CM patients, analysis of potential eligibility for the 'Transthyretin Amyloidosis Cardiomyopathy Clinical Trial' (ATTR-ACT) and identification of factors associated with the decision on tafamidis 61 mg treatment.

Methods And Results: This retrospective study analysed ATTR-CM patients seen at eight University Hospitals in the first year after approval of tafamidis 61 mg for ATTR-CM in Germany (April 2020 to March 2021).

View Article and Find Full Text PDF

A review of professionalism in surgery.

Proc (Bayl Univ Med Cent)

September 2024

Department of Orthopaedics, University of North Carolina, Novant Health, Charlotte, North Carolina, USA.

Article Synopsis
  • Surgeons have distinct expectations and responsibilities when it comes to professionalism, especially due to their interactions with various groups including peers, trainees, and patients in high-stress situations.
  • Effective communication and respectful professional behavior are crucial and are currently adapting to reflect the changing workforce and societal norms.
  • Professionalism is now being formally taught in medical education, with future developments including standardized training modules and connections to surgeon evaluation, credentialing, and reimbursement processes.
View Article and Find Full Text PDF

Exploring Structure-Activity Relationships and Modes of Action of Laterocidine.

ACS Cent Sci

September 2024

Biomedicine Discovery Institute, Infection Program and Department of Pharmacology and Infection Program and Department of Microbiology, Monash University, Melbourne, VIC 3800, Australia.

A significant increase in life-threatening infections caused by Gram-negative "superbugs" is a serious threat to global health. With a dearth of new antibiotics in the developmental pipeline, antibiotics with novel mechanisms of action are urgently required to prevent a return to the preantibiotic era. A key strategy to develop novel anti-infective treatments is to discover new natural scaffolds with distinct mechanisms of action.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!